PNC Financial Services Group Inc. Raises Holdings in Progyny, Inc. (NASDAQ:PGNY)

PNC Financial Services Group Inc. boosted its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 129.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,967 shares of the company’s stock after purchasing an additional 11,268 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Progyny were worth $344,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of PGNY. GAMMA Investing LLC increased its holdings in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after acquiring an additional 1,246 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after acquiring an additional 1,526 shares during the last quarter. Caitlin John LLC increased its holdings in shares of Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after acquiring an additional 3,183 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Progyny in the 4th quarter valued at about $74,000. Finally, KBC Group NV increased its holdings in shares of Progyny by 84.6% in the 4th quarter. KBC Group NV now owns 4,669 shares of the company’s stock valued at $81,000 after acquiring an additional 2,140 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Wall Street Analysts Forecast Growth

PGNY has been the topic of a number of recent analyst reports. Canaccord Genuity Group increased their price objective on Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a report on Friday, February 28th. JPMorgan Chase & Co. increased their price objective on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Finally, Bank of America increased their price objective on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $24.82.

Insiders Place Their Bets

In other Progyny news, Chairman David J. Schlanger bought 150,000 shares of the business’s stock in a transaction dated Thursday, December 26th. The stock was acquired at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the purchase, the chairman now owns 228,269 shares in the company, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Peter Anevski bought 209,500 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were acquired at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the purchase, the chief executive officer now owns 441,463 shares in the company, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is owned by insiders.

Progyny Trading Up 0.8 %

Progyny stock opened at $21.86 on Friday. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $38.98. The stock has a 50 day moving average of $21.93 and a two-hundred day moving average of $18.62. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of 37.69, a PEG ratio of 2.39 and a beta of 1.41.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.